Your AI-Trained Oncology Knowledge Connection!
With the progress in diagnostic methods that has made it possible to decipher the genetic code of DLBCL within a relatively short time, and with the increasing number of drugs that are entering clinical trials, our next big challenge is to enroll patients in trials in a timely manner.
The classification of diffuse large B-cell lymphoma into three distinct molecular diseases--germinal center B-cell–like subtype, an activated B-cell–like subtype, and a primary mediastinal B-cell lymphoma subtype--has laid the foundation for the development of new agents and novel strategies that target individual subtypes.
New trial results show that a novel, oral metabolic inhibitor has demonstrated early activity in relapsed or refractory acute myeloid leukemia (AML), according to data presented at the annual meeting of the American Association of Cancer Research.
A new study of patients with diffuse large B-cell lymphoma (DLBCL) suggests that event-free status at 2 years post-treatment is a useful endpoint both for research and for patient counseling.
A subgroup of chronic myeloid leukemia (CML) cells that were “sticky,” or adherent to plastic, showed higher expression levels of BCR-ABL and were more resistant to treatment with the tyrosine kinase inhibitor imatinib.
A phase II trial of mogamulizumab showed that the agent has meaningful antitumor activity in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma, and acceptable toxicity.
MolecularMD and Novartis are working on a diagnostic test to help determine which chronic myeloid leukemia patients may be candidates to stop taking nilotinib.
Although the cure rate remains high in women who present with bulky mediastinal stage I–II HL, the challenge remains to balance efficacy and minimize long-term toxicities.
Contrary to some previous research as well as popular belief, living underneath or near to power lines as a child may not have any notable effect on childhood leukemia risk, according to a new case-control study conducted in the United Kingdom.
Researchers have identified distinct pre-leukemic hematopoietic stem cells (HSCs) in acute myeloid leukemia (AML) patients.
A score based on an epigenetic signature of hematopoietic stem cells (HSCs) is highly prognostic for patients with acute myeloid leukemia (AML), according to a new study.
The combination of idelalisib with rituximab improved survival in relapsed CLL, and idelalisib also showed antitumor activity as a single agent in patients with indolent non-Hodgkin lymphoma.
Activating mutations in the beta-catenin gene in bone cells is shown to contribute to the development of acute myeloid leukemia.
No definite guidelines exist for the management of nongastric MALT lymphoma. Retrospective series have included patients treated with different modalities, and excellent cause-specific and overall survival have been demonstrated, independent of the type of treatment adopted.
Chronic myeloid leukemia (CML) patients with higher copayments for the tyrosine kinase inhibitor imatinib were more likely to discontinue the drug or be non-adherent, according to a new study.
A deep molecular response to imatinib, achieved by most chronic myeloid leukemia patients who receive the drug, is predictive of better overall survival, according to a new study.
Modulation of the bone marrow microenvironment with parathyroid hormone may be a feasible way to dramatically reduce counts of leukemia stem cells in chronic myeloid leukemia patients, according to new research in mice.
Mesotheliomas that arise after patients receive radiation therapy for lymphoma have unusual histologic features, and those patients tend to be younger and tend to survive longer than more common asbestos-related mesothelioma patients.
A new phase II trial found that a regimen containing rituximab, gemcitabine, cyclophosphamide, vincristine, and prednisolone is active and reasonably safe in patients with diffuse large B-cell lymphoma and coexisting cardiac disease.
A study aimed at defining the natural history of breast implant-associated anaplastic large-cell lymphoma found that outcomes differ between those cases where the disease is confined within the fibrous capsule surrounding the implant and those where a mass is present in the breast.
Although the prospect is tempting, we do not believe there are sufficient grounds at this time to abandon bone marrow biopsy in patients with lymphoma. It still provides robust prognostic information, and in the majority of patients it remains an indispensable staging tool.
Clearly, eliminating a bone marrow biopsy in appropriate patients would be another step in the direction of minimizing the torture to which they are subjected.
Treatment with gemtuzumab ozogamicin improved the event-free survival in children and adolescents with acute myeloid leukemia by reducing the risk of relapse among those able to achieve remission, according to trial results presented at the 2013 ASH meeting.
Ponatinib showed significant antileukemic activity in patients with CML and ALL, according to a phase II study that included a wide range of disease stages and mutation status; patients in the trial had a relatively high rate of adverse thrombotic events, an issue which has led to recent regulatory controversy surrounding the drug.
Following recent trial data showing an increased risk of dangerous blood clots with ponatinib, which led the FDA to request that the manufacturer stop marketing the drug, the FDA’s European counterpart has adjusted its recommendations for ponatinib but has not changed its “positive opinion” that led to the approval.
